{"id":"trazodone-pregabalin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1059","moleculeType":"Small molecule","molecularWeight":"159.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trazodone acts primarily as a serotonin 2A antagonist and serotonin reuptake inhibitor, enhancing serotonergic neurotransmission to reduce anxiety and improve mood. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and providing anxiolytic and analgesic effects. The combination targets both serotonergic and GABAergic pathways to address anxiety with concurrent pain or neuropathic symptoms.","oneSentence":"This is a fixed-dose combination of trazodone (a serotonin antagonist and reuptake inhibitor) and pregabalin (a gabapentinoid that modulates calcium channels) designed to treat anxiety and pain-related conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:14:01.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders with concurrent pain or neuropathic pain symptoms"}]},"trialDetails":[{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00791739","phase":"PHASE4","title":"Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2008-04","conditions":"Fibromyalgia","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Deprax","Lyrica"],"phase":"marketed","status":"active","brandName":"trazodone, pregabalin","genericName":"trazodone, pregabalin","companyName":"Universidad de Granada","companyId":"universidad-de-granada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trazodone and pregabalin are medications that have been studied in clinical trials for various conditions, including fibromyalgia, depression, and schizophrenia. Pregabalin is a small molecule that modulates voltage-gated calcium channels, which is its primary mechanism of action.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}